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Objectives: A multicenter study to compare results of BRAHMS Kryptor PCT with those obtained using
four BRAHMS-partnered procalcitonin (PCT) automated immunoassays (DiaSorin Liaison, BioMérieux
Vidas, Roche Cobas E601 and Siemens Advia Centaur) and the Diazyme immunotubidimetric assay im-
plemented on four clinical chemistry platforms (Abbott Architect c16000, Siemens Advia 2400, Roche
Cobas C501 and Beckman Coulter AU5800).
Design and methods: One hundred serum samples from in-patients with PCT values between 0.10 and
58.7 ng/mL were divided into aliquots and tested with the nine different reagents and analyzers.
BRAHMS PCT Kryptor results were used as reference.
Results: Compared to BRAHMS PCT Kryptor, signiﬁcant differences in results were observed on Vidas,
Advia Centaur, Architect, Cobas C501 and AU5800. However, the correlation coefﬁecients (r) with
BRAHMS PCT Kryptor were between 0.899 and 0.988. The mean bias was less than 71.02 ng/mL, except
for Vidas (2.70 ng/mL). The agreement at three clinically relevant cut-offs was optimal: between 83–98%
at 0.50 ng/mL, 90–97% at 2.0 ng/mL, and 98% at 10 ng/mL. The comparison of Diazyme PCT across the four
clinical chemistry analyzers yielded high correlation coefﬁcients (r between 0.952 and 0.976), a mean
bias less than 70.9 ng/mL, acceptable agreement at 0.5 ng/mL (482%), and high concordance at the
2.0 ng/mL (497%) and 10 ng/mL (498%) cut-offs.
Conclusions: The methods and applications evaluated in this multicenter study are aligned with BRAHMS
PCT Kryptor and can be used for predicting the risk of progression to systemic inﬂammation in patients
with bacterial infections using the conventional PCT diagnostic thresholds.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Procalcitonin (PCT), a 116 amino acid peptide with molecular weight 14.5 kDa, belongs to the calcitonin superfamily of peptides. The
protein is encoded by the CALC-1 (Calcitonin Gene-related Peptide 1) gene on chromosome 11 [1]. The original product of this gene, a 141
amino acid peptide known as pre-PCT, undergoes a proteolytic cleavage of the 25 amino acid signal peptide to produce the PCT molecule,
which is then further processed to generate the mature, 32 amino acid-long calcitonin. Under physiological conditions, the transcription of
CALC-1 gene is suppressed in non-neuroendocrine tissues, so that the C cells of the thyroid gland are responsible for the entire synthesis of
PCT and calcitonin [1].
In the presence of microbial infections, the synthesis of PCT is dramatically ampliﬁed in all parenchymal tissues and differentiated cell
types, so that its concentration in blood may increase by several orders of magnitude, up to one thousand-fold [1]. The PCT response to the
infection closely mirrors the severity of the inﬂammatory reaction. More speciﬁcally, higher values are associated with severe disease,r B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
a, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy.
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monitoring of bacterial infections. In particular, PCT values between Z0.5 and 2.0 ng/mL are suggestive of moderate risk for progression to
systemic inﬂammation, between 2.0 and 10 ng/mL are suggestive for high risk for progression to systemic inﬂammation, whereas values
Z10 ng/mL are associated with a high probability of developing severe sepsis and septic shock [1]. Recent evidence also suggests that the
measurement of PCT may be helpful for the diagnosis of bacterial peritonitis [3], as well as for guiding antibiotic therapy in patients with
localized (i.e., community acquired pneumonia) and systemic bacterial infections [4].
Although there is currently no agreed reference technique for PCT measurement, the BRAHMS PCT Kryptor method has been directly
developed from the original BRAHMS luminometric immunoassay (LIA), and was the ﬁrst automated method cleared by the FDA for the
diagnosis of severe sepsis and septic shock [5]. Several diagnostic companies such as DiaSorin, BioMérieux, Siemens and Roche have since
partnered with BRAHMS for developing automated PCT assays on their proprietary platforms, using different technologies (i.e., im-
munoluminometric, enzyme-linked immunoﬂuorescent, chemiluminescent and electrochemiluminescent immunoassays). More recently,
a latex-enhanced immunotubidimetric assay has also been developed by Diazyme, to be used on a vast array of clinical chemistry ana-
lyzers. Nevertheless, due to the lack of a PCT reference material, it remains uncertain whether the current clinical PCT cut-offs would apply
to all the available procalcitonin immunoassays, or if monitoring using different methods would be clinically reliable when patients are
transferred between healthcare facilities. Therefore, the aim of this multicenter study was to compare results of the BRAHMS Kryptor PCT
with those obtained using four BRAHMS-partnered PCT automated immunoassays and the Diazyme immunotubidimetric assay im-
plemented on four different clinical chemistry platforms.2. Materials and methods
2.1 Study design
This multicenter study was based on 100 serum samples from inpatients (52 from the intensive care unit, 12 from the emergency
department, 15 from the infective diseases unit and 21 from other medical and surgical wards) referred to the laboratory of the University
Hospital of Parma for routine PCT measurement during a single working day. The samples were selected to cover the most clinically
signiﬁcant PCT concentrations (0.10–58.7 ng/mL) measured using the local routine immunoassay (BRAHMS PCT Kryptor system, BRAHMS,
Hennigsdorf, Germany) (Fig. 1). The blood samples were immediately centrifuged upon arrival in the laboratory, serum was separated and
divided into seven aliquots of 0.6 mL each. The ﬁrst aliquot was used for routine PCT assessment, whereas the remaining six aliquots were
frozen at 70 °C. After one week of storage, the aliquots were transported to the participating centers, under controlled conditions of
temperature and humidity. Speciﬁcally, four reusable dry gel packs containing carbopol gel (2200 mL and 2500 mL) were frozen at
70 °C and then placed into certiﬁed transport boxes at the sample collection center [6]. The mean time of shipment to the participating
centers was 92 min (range: 54–106 min). Upon arrival, the aliquots were stored frozen at 70 °C until all sites had received the shipment.
The aliquots were then thawed at room temperature on the same day, and simultaneously analyzed in each center with all reagents and
methods, including retesting on BRAHMS PCT Kryptor.
2.2 Methods description
The complete description of reagents and instrumentation is shown in Table 1. In brief, the BRAHMS PCT Kryptor system is anFig. 1. Distribution of procalcitonin values (median and interquartile range) obtained with the different reagents and instruments (see Table 1 for details).
Table 1
Description of sites, reagents and instruments used in the multicenter study.
Site Company Method Assay principle Sample volume (mL) Measuring range (ng/mL)
Parma, Italy BRAHMS, Hennigsdorf, Germany Kryptor BRAHMS PCT sensitive Time-Resolved Ampliﬁed Cryptate Emission (TRACE)
immunoassay
50 0.02–1000
Asti, Italy Diasorin, Saluggia (VC), Italy Liaison BRAHMS PCT Two-site immunoluminometric assay 100 0.02–100
Lodi, Italy bioMérieux, Marcy l’Etoile, France Vidas BRAHMS PCT Enzyme-linked ﬂuorescent immunoassay (ELFA) 200 0.05–200
Milano, Italy Roche Diagnostics, Mannheim, Germany Roche BRAHMS PCT Electrochemiluminescence immunoassay (ECLIA) 30 0.02–100
Alessandria, Italy Siemens Diagnostics, Marburg, Germany Siemens BRAHMS PCT One-step chemiluminescence immunoassay 100 0.02–75
Bassano del Grappa, Italy Abbott Diagnostics Abbott Park, Illinois, U.S.A Diazyme procalcitonina Latex-enhanced immunotubidimetric assay 20 0.16–56
Alessandria, Italy Siemens Healthcare Diagnostics, Marburg,
Germany
Diazyme procalcitonina Latex-enhanced immunotubidimetric assay 20 0.16–56
Milano, Italy Roche Diagnostics, Mannheim, Germany Diazyme procalcitonina Latex-enhanced immunotubidimetric assay 20 0.16–56
Parma, Italy Beckman Coulter Inc., Brea, CA, USA Diazyme procalcitonina Latex-enhanced immunotubidimetric assay 20 0.16–56
a Diazyme procalcitonin, Diazyme Laboratories, Poway, CA, USA.
M
.D
ipalo
et
al./
Practical
Laboratory
M
edicine
2
(2015)
22
–28
24
M. Dipalo et al. / Practical Laboratory Medicine 2 (2015) 22–28 25immunoﬂuorescent, fully automated and highly sensitive PCT assay. The measurement principle is based on Time-Resolved Ampliﬁed
Cryptate Emission (TRACE) technology, entailing the measurement of a signal emitted from an immunocomplex with time delay. The
functional sensitivity and total imprecision (coefﬁcient of variation, CV) of the assay were previously found to be 0.04 ng/mL and 0.7–8.3%,
respectively [7]. Serum procalcitonin was also measured using four BRAHMS-partnered PCT automated immunoassays, the analytical
characteristics of which have been previous described elsewhere and are brieﬂy reported in Table 1 [8–12].
Diazyme PCT (Diazyme Laboratories, Poway, CA, USA) is a latex-enhanced immunoturbidimetric assay, which has been developed for
use on a wide array of laboratory analyzers capable of reading absorbance at 600 nm. According to the test procedure, the PCT present in
the serum sample binds to speciﬁc anti-PCT antibodies coated on latex particles and trigger their agglutination. The turbidity is then
measured at 600 nm and is directly proportional to the concentration of PCT in the sample. The ﬁnal PCT value is calculated by inter-
polation of optical signal against a 6-point calibration curve. The amount of sample required for testing is 20 μL and the ﬁrst test result is
available in 10 min. In this study, Diazyme PCT was measured on four different clinical chemistry platforms, using the same assay protocol
(Table 1). According to a previous analytical evaluation, the lowest measurable value and the total imprecision were found to be
0.16 ng/mL and 2.9–7.7%, respectively [13].
According to the manufacturers’ literature, the inter- and intra-assay imprecision (CV) of the other immunoassays used in this study is
2.0–3.8% and 3.2–9.5%, respectively for Liaison BRAHMS PCT; 1.9–4.6% and 3.6–7.0%, respectively for Vidas BRAHMS PCT; and 1.1–7.1% and
1.6–8.7%, respectively for Roche BRAHMS PCT. The manufacturer’s quoted total imprecision for Siemens BRAHMS PCT is o11%.
2.3 Statistical analysis
The results obtained using the different methods and analyzers were compared with those obtained with BRAHMS PCT Kryptor.
Method comparison was based on Wilcoxon–Mann–Whitney paired rank sum test, Deming ﬁt, Spearman’s correlation coefﬁcient, Bland-
Altman difference plots, receiver operating characteristics (ROC) curves, and agreement at three clinically relevant cut-offs for bacterial
infections (i.e., 0.50 ng/mL, 2.0 ng/mL and 10 ng/mL) with kappa statistic. The statistical analysis was performed using Analyse-it (Analyse-
it Software Ltd, Leeds, UK) and the level of statistical signiﬁcance was set at po0.05. The analytical evaluation was entirely based on pre-
existing inpatient serum samples referred for routine PCT testing, so that informed patient consent was unnecessary. However, the study
was carried out in accordance with the Declaration of Helsinki and under the terms of all relevant local legislation.3. Results
No signiﬁcant decay of PCT immunoreactivity was observed after one week of storage at 70 °C, as attested by the negligible bias
observed between fresh and frozen serum analyzed with BRAHMS PCT Kryptor (mean 0.05 ng/mL; 95% CI, 0.12 to 0.010 ng/mL;
p¼0.097). The distribution of PCT values obtained with different reagents and analyzers is shown in Fig. 1. Statistically signiﬁcant dif-
ferences compared to BRAHMS PCT Kryptor were observed for two BRAHMS-partnered PCT automated immunoassays (Vidas BRAHMS
PCT and Advia Centaur BRAHMS PCT) and for three Diazyme PCT applications on Architect, Cobas C501 and AU5800 (Table 2). Never-
theless, the correlation between BRAHMS PCT Kryptor and the different methods and applications was always satisfactory, with corre-
lation coefﬁcients between 0.899 and 0.988 (all po0.001). The mean bias was also limited and always lower than 71.02 ng/mL, with the
exception of Vidas BRAHMS PCT (2.70 ng/mL) (Table 2 and Fig. 2). Interestingly, this bias was mostly attributable to overestimation at PCT
values higher than 10 ng/mL with Vidas BRAHMS PCT (mean bias 11.6 ng/mL, 95% CI 8.1–15.1 ng/mL for PCT values 410 ng/mL compared
to mean bias of 0.6 ng/mL and 95% CI 0.04–1.19 ng/mL PCT for values o10 ng/mL) (Fig. 2). Other interesting information emerged from the
comparison. Speciﬁcally, the bias between results obtained with BRAHMS PCT Kryptor and Advia Centaur BRAHMS PCT appeared to follow
a speciﬁc linear pattern, characterized by overestimation of lower PCT values and underestimation of higher PCT concentration with the
Advia immunoassay. Some outliers were also evident in almost every plot, but were more frequently observed for higher PCT values
measured with Diazyme PCT applications (Fig. 2).
Overall, the agreement and the area under the curve (AUC) at the three clinically relevant cut-offs for bacterial infections were always
satisfactory, with classiﬁcation concordance between 83 and 98% at 0.50 ng/mL, between 90 and 97% at 2.0 ng/mL, and 98% at 10 ng/mL
(Table 3). The direct comparison of data obtained with the Diazyme PCT assay on the four clinical chemistry analyzers yielded high
correlation coefﬁcients (between 0.952 and 0.976; all po0.001), a mean bias always less than 70.9 ng/mL, an acceptable classiﬁcation
agreement at the 0.5 ng/mL threshold (82–94%), and a high classiﬁcation concordance at both the 2.0 ng/mL (97–99%) and 10 ng/mL (98–
100%) cut-offs (Table 4).Table 2
Results obtained with procalcitonin immunoassays compared to BRAHMS PCT Kryptor.
Values (ng/mL)a P (Wilcoxon–Mann–Whitney)b Spearman's correlation (r)b Deming ﬁtb Mean bias and 95% CI (ng/mL)b
Kryptor 1.40 (0.35–5.37) – – – –
Liaison 1.63 (0.32–5.78) 0.052 0.986 (po0.001) y¼1.02xþ0.22 0.38 (0.08 to 0.83)
Vidas 1.95 (0.33–6.40) o0.001 0.979 (po0.001) y¼1.40x0.09 2.70 (1.55 to 3.86)
Cobas E601 1.30 (0.30–4.90) 0.085 0.988 (po0.001) y¼1.12x0.47 0.40 (0.17 to 0.97)
Advia Centaur 1.35 (0.32–5.11) 0.001 0.984 (po0.001) y¼0.80xþ0.40 1.02 (1.67 to 0.36)
Diazyme (Architect) 1.27 (0.28–4.53) 0.038 0.899 (po0.001) y¼0.95x0.16 0.51 (1.07 to 0.06)
Diazyme (Advia 2400) 0.88 (1.15–4.46) 0.341 0.927 (po0.001) y¼1.01x0.23 0.13 (0.77 to 0.51)
Diazyme (Cobas C501) 0.90 (0.48–4.38) 0.004 0.899 (po0.001) y¼0.85xþ0.07 1.01 (1.76 to 0.26)
Diazyme (AU5800) 0.82 (0.42–4.82) 0.002 0.899 (po0.001) y¼0.87x0.04 0.87 (1.47 to 0.27)
a Median and interquartile range.
b Versus BRAHMS PCT Kryptor.
Fig. 2. Bland and Altman plots of results obtained with different procalcitonin immunoassays (see Table 1 for details) compared to BRAHMS PCT Kryptor. The continuous line
represents the mean bias, and the dotted lines are drawn at the 95% conﬁdence interval (95% CI).
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The clinical value of measuring PCT for the diagnosis, follow-up and antibiotic guidance of severe bacterial infections has been con-
ﬁrmed in a large number of clinical trials [14–16], leading to the commercialization of many immunoassays to be used on conventional
Table 3
Agreement of results obtained with different procalcitonin immunoassays compared to BRAHMS PCT Kryptor at three diagnostic thresholds.
Procalcitonin cut-off
(ng/mL)
Liaison Vidas Cobas E601 Advia Centaur Diazyme
(Architect)
Diazyme (Advia
2400)
Diazyme (Cobas
C501)
Diazyme
(AU5800)
0.5 97% (κ, 0.93)
AUC, 0.96
97% (κ, 0.93)
AUC, 0.98
98% (κ, 0.95)
AUC, 0.99
95% (κ, 0.89)
AUC, 0.95
84% (κ, 0.66) AUC,
0.86
86% (κ, 0.70)
AUC, 0.89
86% (κ, 0.65)
AUC; 0.81
83% (κ, 0.60) AUC,
0.80
2.0 96% (κ, 0.92)
AUC, 0.96
94% (κ, 0.88)
AUC, 0.95
97% (κ, 0.94)
AUC, 0.97
96% (κ, 0.92)
AUC, 0.96
90% (κ, 0.80) AUC,
0.89
91% (κ, 0.82)
AUC, 0.91
92% (κ, 0.84)
AUC, 0.92
91% (κ, 0.82) AUC,
0.90
10.0 98% (κ, 0.94)
AUC, 0.97
98% (κ, 0.94)
AUC, 0.99
98% (κ, 0.94)
AUC, 0.97
98% (κ, 0.94)
AUC, 0.96
98% (κ, 0.94) AUC,
0.96
98% (κ, 0.94)
AUC, 0.96
98% (κ, 0.94)
AUC, 0.95
98% (κ, 0.94) AUC,
0.98
AUC, area under the curve.
Table 4
Comparison of procalcitonin results obtained with Diazyme latex-enhanced immunotubidimetric assay on four different clinical chemistry platforms.
Architect Advia 2400 Cobas C501
Advia 2400 r¼0.976 (po0.001) Biasa, 0.37 ng/mL (0.05–
0.70 ng/mL) Agreementb, 94%; 99%; 100%
– –
Cobas C501 r¼0.964 (po0.001) Biasa, 0.50 ng/mL (0.97 to
–0.04 ng/mL) Agreementb, 84%; 98%; 98%
r¼0.968 (po0.001) Biasa, 0.88 ng/mL (1.35 to
0.40 ng/mL) Agreementb, 82%; 99%; 98%
–
AU5800 r¼0.958 (po0.001) Biasa, 0.36 ng/mL (0.65 to
0.07 ng/mL) Agreementb, 85%; 97%; 98%
r¼0.962 (po0.001) Biasa, 0.74 ng/mL (1.18 to
0.29 ng/mL) Agreementb, 87%; 98%; 98%
r¼0.952 (po0.001) Biasa, 0.14 ng/mL (0.22 to
0.50 ng/mL) Agreementb, 89%; 97%; 98%
a Mean bias and 95% Conﬁdence Interval (95% CI).
b Classiﬁcation agreement calculated at 0.5, 2.0 and 10 ng/mL cut-offs.
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developed latex-enhanced immunoturbidimetric assay which can be applied to several analytical platforms. Although some studies have
previously evaluated the individual performance of some of these techniques [8–13], a comprehensive method comparison using identical
serum samples has not been previously published to our knowledge. It is also noteworthy that no data are available on the direct
comparison of Diazyme PCT results obtained on different clinical chemistry platforms.
The results of our multicenter evaluation suggest that the different reagents and techniques exhibit comparable performance at the
three relevant diagnostic thresholds for bacterial infections. In particular, the agreement at the 2.0 and 10 ng/mL cut-offs, which reﬂect a
moderate and high risk for progression to systemic inﬂammation, sever sepsis and septic shock, was excellent, displaying an overall
classiﬁcation concordance equal to or better than 90% with our reference method (BRAHMS PCT Kryptor) (Table 3). The agreement of data
obtained using Diazyme PCT on four different clinical chemistry platforms was even better at these thresholds, ranging between 97% and
100% (Table 4). Regardless of the satisfactory correlation of values, a modest bias was still observed using different reagents and analyzers
(Table 2), especially at PCT values higher than 10 ng/mL (Fig. 2). This was particularly evident when comparing BRAHMS PCT Kryptor with
Vidas BRAHMS PCT and was mostly attributable to overestimation by the Vidas method at PCT serum concentration 410 ng/mL. Inter-
estingly, a previous evaluation of Vidas BRAHMS PCT reported a lower bias against BRAHMS PCT Kryptor (i.e., 0.108 ng/mL), but an
identical trend of overestimation in samples with PCT values 410 mg/L [10]. The overall agreement between BRAHMS PCT Kryptor and
Vidas BRAHMS PCT at the 0.1, 0.25, 0.5 and 2 ng/mL thresholds in that study was however excellent (496%), and comparable to that
observed in our investigation (Table 3). The mean bias observed with the other reagents and instrumentation was modest (between
1.02 ng/ml and 0.40 ng/mL). This small difference does not substantially impact on the diagnosis of sepsis or classifying disease severity
according to the current diagnostic cutoffs, but supports the hypothesis that the different methods cannot be used interchangeably for
patient monitoring. Interestingly, the results obtained with the four Diazyme PCT applications were well correlated and substantially
aligned with each other (Table 4), but they all exhibited a negative bias compared to BRAHMS PCT Kryptor, a fact that is probably
attributable to the use of different calibrators. In this respect, the development and use of a common calibration material should be
regarded as a viable proposition for improving agreement between methods.5. Conclusions
The results of our investigation demonstrate that the methods and applications evaluated in this multicenter study are substantially
aligned with BRAHMS PCT Kryptor, and can hence be used for predicting the risk of progression to systemic inﬂammation, severe sepsis
and septic shock in patients with bacterial infections using the conventional PCT diagnostic thresholds. Nevertheless, the varying bias
between by the different methods indicates that longitudinal patient monitoring should preferably always be carried out using the same
immunoassay.Conﬂict of interest
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